Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04486781
Title A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vasgene Therapeutics, Inc
Indications

transitional cell carcinoma

Therapies

Pembrolizumab + sEphB4-HSA

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.